InvestorsHub Logo
Followers 1008
Posts 70422
Boards Moderated 4
Alias Born 09/30/2004

Re: Golden Cross post# 1470

Wednesday, 01/15/2020 8:45:56 AM

Wednesday, January 15, 2020 8:45:56 AM

Post# of 1724
Should see a correction higher heading in to Conference Call next week. Company just given 9-10 figure deal with Bayer and trading for about a $35 million valuation. Big upside here in 2020 imo.


Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene(R) Licensing Agreement and General Corporate Update

8:00 AM ET 1/15/20 | GlobeNewswire

Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene(R) Licensing Agreement and General Corporate Update

SAN DIEGO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020, to discuss the recently announced licensing agreement with Bayer and Daré's broader partnering strategy, and to provide a general corporate update.

To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 2855687. The live webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 2855687. The call and webcast replay will be available until February 5, 2020.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DARE News